anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Neurokinin receptor 1 antagonists are effective in reducing nausea and vomiting in chemotherapy-induced emesis. We investigated the safety and efficacy of tradipitant, a neurokinin receptor 1 antagonist, in patients with idiopathic and diabetic gastroparesis.
METHODS: A total of 201 adults with gastroparesis were randomly assigned to oral tradipitant 85 mg (n = 102) or placebo (n = 99) twice daily for 12 weeks. Symptoms were assessed by a daily symptom dairy, Gastroparesis Cardinal Symptom Index scores, and other patient-reported questionnaires. Blood levels were monitored for an exposure-response analysis. The primary outcome was change from baseline to week 12 in average nausea severity, measured by daily symptom diary.
RESULTS: The intention-to-treat (ITT) population did not meet the prespecified primary endpoint at week 12 (difference in nausea severity change drug vs placebo; P = .741) or prespecified secondary endpoints. Post hoc analyses were performed to control for drug exposure, rescue medications, and baseline severity inflation. Subjects with high blood levels of tradipitant significantly improved average nausea severity beginning at early time points (weeks 2-4). In post hoc sensitivity analyses, tradipitant treatment demonstrated strengthened effects, with statistically significant improvements in nausea at week 12.
CONCLUSIONS: Although tradipitant did not reach significance in the ITT population, a pharmacokinetic exposure-response analysis demonstrated significant effects with adequate tradipitant exposure. When accounting for confounding factors such as baseline severity inflation and rescue medication, a statistically significant effect was also observed. These findings suggest that tradipitant has potential as a treatment for the symptom of nausea in gastroparesis. (ClincialTrials.gov, Number: NCT04028492).
OBJECTIVE: We present an unusual case of a small para-aortic lymphocele causing duodenal stenosis after lymphadenectomy and discuss its treatment.
CASE REPORT: Our case involved a 57-year-old woman with endometrial cancer who underwent surgery, including para-aortic lymphadenectomy. On postoperative day 7, projectile vomiting occurred. Computed tomography (CT) revealed a small lymphocele in the dorsal duodenum, causing duodenal stenosis. Transpercutaneous and transduodenal puncture or surgical procedures were difficult because the cyst was too small. Per endoscopic and gastrointestinal series findings on the postoperative day 22, a liquid diet was presumed to be able to pass through the narrow portion. Hence, concentrated liquid food was administered orally; no vomiting occurred. At 2 months postoperatively, CT showed no lymphocele.
CONCLUSION: Conservative treatment involving waiting for spontaneous lymphocele reduction with a concentrated fluid diet may be considered in such cases if fluid passage is confirmed with endoscopy and gastrointestinal series.
The invention discloses a nano silver high-efficiency antibacterial composition used for gynecologic inflammation and a preparation method thereof. The acting component in the formation of the nano silver high-efficiency antibacterial composition is nano silver, and the composition comprises two parts which are respectively a nano silver vaginal effervescent tablet and a slow-release tablet. The invention is suitable for female vaginal application and combined use. When in use, the effervescent tablet is firstly dissolved into water, an affected part is washed, then the slow-release tablet is put into the mixture, the principle of the release of a medicine can be fully utilized, and the sufficient and uniform medicine concentration is ensured, thereby killing pathogenic bacteria quickly and thoroughly and achieving the aim of cure. The combination has convenient use, is also convenient to carry, is easily accepted by a patient and is suitable for clinical popularization and use. The invention also discloses the preparation method. The invention has stable quality of a product, simple preparation process, controllable quality and lower cost, can adapt to industrialized large-scale production, ensures the quality of the product and can also lower the application burden of illness greatly. The composition prepared by the invention is mainly applied to vaginitis, urethritis, pelvic inflammation, cervicitis and the like in the gynecologic inflammation, and the cure rate can reach 90.3 percent.
BACKGROUND: The anticipatory prescribing of injectable controlled drugs (ICDs) by general practitioners (GPs) to care home residents is common practice and is believed to reduce emergency hospital transfers at the end-of-life. However, evidence about the process of ICD prescribing and how it affects residents' hospital transfer is limited. The study examined how care home nurses and senior carers (senior staff) describe their role in ICDs prescribing and identify that role to affect residents' hospital transfers at the end-of-life.
METHODS: 1,440 h of participant observation in five care homes in England between May 2019 and March 2020. Semi-structured interviews with a range of staff. Interviews (n = 25) and fieldnotes (2,761 handwritten A5 pages) were analysed thematically.
RESULTS: Senior staff request GPs to prescribe ICDs ahead of residents' expected death and review prescribed ICDs for as long as residents survive. Senior staff use this mechanism to ascertain the clinical appropriateness of withholding potentially life-extending emergency care (which usually led to hospital transfer) and demonstrate safe care provision to GPs certifying the medical cause of death. This enables senior staff to facilitate a care home death for residents experiencing uncertain dying trajectories.
CONCLUSION: Senior staff use GPs' prescriptions and reviews of ICDs to pre-empt hospital transfers at the end-of-life. Policy should indicate a clear timeframe for ICD review to make hospital transfer avoidance less reliant on trust between senior staff and GPs. The timeframe should match the period before death allowing GPs to certify death without triggering a Coroner's referral.
FIELD: medicine. SUBSTANCE: invention relates to medicinal agents with an antihypoxic effect. Invention proposes an agent that is an aqueous 10-18% solution of sodium fumarate. The medicinal agent can be used as a component in any schedules of infusion-transfusion therapy. The preparation eliminates the metabolic acidosis and shows antioxidant properties also. EFFECT: valuable medicinal properties of preparation. 1 cl, 3 tbl, 2 ex
Subjects randomized to have the right side of the face peeled with salicylic acid every 2 weeks for a total of 4 peels (first 2 at 20% and last 2 at 30%). Subjects will apply 4% hydroquinone cream to affected areas on entire face for 14 weeks.
Aerobic exercise will be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking and dynamic exercises. A 5-min walking cool down will end the session. The training dose for this arm is 750 MET-min/wk for 3-5 days per week, 22-45 minutes per session at a moderate to vigorous intensity. The exercise can be completed in person or virtually.
### 

Teratogenic Effects: Pregnancy Category B. Acyclovir administered during organogenesis was not teratogenic in the mouse (450 mg/kg/day, p.o.), rabbit (50 mg/kg/day, s.c. and IV), or rat (50 mg/kg/day, s.c.). These exposures resulted in plasma levels 9 and 18, 16 and 106, and 11 and 22 times, respectively, human levels. 

There are no adequate and well-controlled studies in pregnant women. A prospective epidemiologic registry of acyclovir use during pregnancy was established in 1984 and completed in April 1999. There were 749 pregnancies followed in women exposed to systemic acyclovir during the first trimester of pregnancy resulting in 756 outcomes. The occurrence rate of birth defects approximates that found in the general population. However, the small size of the registry is insufficient to evaluate the risk for less common defects or to permit reliable or definitive conclusions regarding the safety of acyclovir in pregnant women and their developing fetuses. Acyclovir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Hypoglycemia: See PRECAUTIONS and OVERDOSAGE Sections.

Gastrointestinal Reactions: Cholestatic jaundice and hepatitis may occur rarely which may progress to liver failure; glyburide tablets should be discontinued if this occurs. Liver function abnormalities, including isolated transaminase elevations, have been reported. Gastrointestinal disturbances, e.g., nausea, epigastric fullness, and heartburn, are the most common reactions and occur in 1.8% of treated patients. They tend to be dose-related and may disappear when dosage is reduced.

Dermatologic Reactions: Allergic skin reactions, e.g., pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions, occur in 1.5% of treated patients. These may be transient and may disappear despite continued use of glyburide tablets. Bullous reactions, erythema multiforme, and exfoliative dermatitis, have been reported. If skin reactions persist, the drug should be discontinued.

Porphyria cutanea tarda and photosensitivity reactions have been reported with sulfonylureas.

Hematologic Reactions: Leukopenia, agranulocytosis, thrombocytopenia, which occasionally may present as purpura, hemolytic anemia, aplastic anemia, and pancytopenia have been reported with sulfonylureas.

Metabolic Reactions: Hepatic porphyria reactions have been reported with sulfonylureas; however, these have not been reported with glyburide. Disulfiram-like reactions have been reported very rarely with glyburide. Cases of hyponatremia have been reported with glyburide and all other sulfonylureas, most often in patients who are on other medications or have medical conditions known to cause hyponatremia or increase release of antidiuretic hormone. The syndrome of inappropriate antidiuretic hormone (SIADH) secretion has been reported with certain other sulfonylureas, and it has been suggested that these sulfonylureas may augment the peripheral (antidiuretic) action of ADH and/or increase release of ADH. Glyburide can cause weight gain.

Other Reactions: Changes in accommodation and/or blurred vision have been reported with glyburide and other sulfonylureas. These are thought to be related to fluctuation in glucose levels.

In addition to dermatologic reactions, allergic reactions such as angioedema, arthralgia, myalgia and vasculitis have been reported.
PURPOSE: A cancer therapeutic material containing mineral powder such as loess, zeolite, illite or the like, a herbal extract, chitosan or the like is provided. It is effective in treating cancer without causing adverse effects to healthy tissues by fomentation of a body member and the whole body. CONSTITUTION: Loess, zeolite, illite, jades, quartz porphyry and the like are ground to 325 meshes and formed into a ball with a size of 2 to 6mm respectively. The jades and zeolite balls, illite and quartz porphyry balls, and loess ball are sintered at 650 to 700deg.C, 800 to 900deg.C and 1,250deg.C respectively and mixed. Ginkgo leaves, pine needles, mugwort, green tea leaves, ginseng and Citrus are heated in water at 80deg.C and cooled to -2deg.C. Oyster and clam shells are ground to 325 meshes and formed into a ball with a size of 2 to 3mm. Then, 70% by weight of mineral balls are mixed with 30% by weight of the oyster and clam shell ball to give the cancer therapeutic material. According to the kind of a cancer patient, the cancer therapeutic material is mixed with 30 to 60% by weight of the herbal extract and 40 to 70% by weight of chitosan and citric acid.
BACKGROUND/AIM: Sarcopenia is diagnosed based on grip strength and skeletal muscle mass. Although decreased skeletal muscle mass has been reported to be associated with poor outcomes after hepatectomy, a few studies have included data on grip strength in hepatectomy candidates. This multicenter study investigated the clinical factors and postoperative complications associated with sarcopenia by assessing the grip strength and skeletal muscle mass in patients undergoing hepatectomy for hepatocellular carcinoma (HCC).
PATIENTS AND METHODS: Data from patients who underwent hepatectomy for HCC between January 2020 and March 2022 were retrospectively collected from multi-institutional databases. Sarcopenia was defined as reduced grip strength and skeletal muscle mass. The patients were categorized into the sarcopenia and non-sarcopenia groups, and baseline characteristics and short term outcomes were compared between the two groups.
RESULTS: Overall, 253 patients were included, among which 36 (14.2%) had sarcopenia. The sarcopenia group was significantly associated with older age, low body mass index, comorbid heart or chronic pulmonary disease, cerebrovascular accident history, and overall and major postoperative complications compared to the non-sarcopenia group. Among major postoperative complications [Clavien-Dindo classification (CDC) ≥III], the incidence of bile leakage and intra-abdominal abscess were higher in the sarcopenia group than in the non-sarcopenia group. Multivariate analysis revealed that sarcopenia was an independent risk factor for overall and major postoperative complications (CDC ≥III).
CONCLUSION: Sarcopenia, defined by grip strength and skeletal muscle mass, is a predictor of overall and major complications after hepatectomy for HCC.
OBJECTIVES: I. Estimate the lowest dose of deoxycytidine (dC) that can be given as a host protective agent in conjunction with high dose cytarabine (HD ARA-C) in patients with refractory acute myelogenous leukemia or other hematologic malignancies. II. Determine the maximum tolerated dose and dose-limiting toxic effects of HD ARA-C/dC in these patients. III. Characterize the pharmacokinetics of continuously administered HD ARA-C/dC in these patients. IV. Characterize, when possible, the pharmacodynamics of HD ARA-C, dC, and their metabolites in blasts obtained from leukemic patients participating in this trial. V. Recommend the lowest possible dose of dC that can be given in combination with HD ARA-C in future phase II trials.

OUTLINE: This is a dose escalation study. Patients receive deoxycytidine IV over 120 hours. Beginning 12 hours after initiation of deoxycytidine, patients receive high dose cytarabine IV over 96 hours. Patients achieving complete response receive no further therapy. Patients achieving partial response or initial complete response and subsequent relapse receive an additional course of therapy. Cohorts of 3-6 patients receive escalating doses of deoxycytidine and high dose cytarabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicities.

PROJECTED ACCRUAL: Approximately 24-30 patients will be accrued for this study.
The present invention provides novel genes and polypeptides derived therefrom encoding a redox-sensitive protein that promotes cell growth, protects cells from apoptosis, scavenges oxygen radicals and can be used for the reversion of a tumor phenotype. In an attempt to identify gene(s) responsible for 1,10-phenanthroline (OP)-induced apoptosis in tumor cells we have used the differential display technique and cloned an OP-inducible gene, SAG (Sensitive to Apoptosis Gene). SAG encodes a novel, redox-sensitive, heme-binding protein with a zinc RING finger domain. The SAG protein consists of 113 amino acids with a calculated molecular weight of 12.7 kDa. Antisense SAG transfection inhibits certain tumor cell phenotypes in DLD1 human cell line and microinjection of SAG RNA stimulates cell growth. We propose that SAG protein is a cellular protective molecule functioning as a redox sensor to buffer oxidative-stress induced damage as well as a growth factor to stimulate cell growth. SAG protein will be an ideal molecular target in the development of drugs against neurodegenerative disorders, cancers, muscle dystrophy, and promoting wound healing.
Liver fibrosis is a key and reversible stage in the progression of many chronic liver diseases to cirrhosis or hepatocellular carcinoma. Forsythiaside-A (FTA), a main compound isolated from Forsythiae Fructus, has an excellent liver protective activity. This study aims to investigate the efficacy of FTA in improving cholestatic liver fibrosis. Bile-duct-ligation (BDL) was conducted to induce liver fibrosis in mice. Hepatic collagen deposition was evaluated by Masson and Sirus red staining. The bile acid spectrum in the liver and serum was analyzed by mass spectrometry. Liver oxidative stress injury and mitochondria damage were observed by using Mito-Tracker Red fluorescence staining, transmission electron microscopy, etc. The level of ferrous iron (Fe2+) and the expression of ferroptosis-associated molecules were detected. The binding between FTA and its target protein was confirmed by Co-immunoprecipitation (Co-IP), cellular thermal shift assay (CETSA), drug affinity responsive target stability (DARTS) and surface plasmon resonance (SPR). Our results demonstrated that FTA alleviated BDL-induced liver fibrosis in mice. FTA did not decrease the elevated amount of bile acids in BDL-treated mice, but reduced the bile acid-induced mitochondrial damage, oxidative stress and ferroptosis in hepatocytes, and also induced nuclear factor erythroid 2-related factor-2 (Nrf2) activation. In Nrf2 knock-out mice, the FTA-provided protection against BDL-induced liver fibrosis was disappeared, and FTA's inhibition on mitochondrial damage, oxidative stress and ferroptosis were lowered. Further results displayed that FTA could directly bind to Kelch-like ECH-associated protein-1 (Keap1), thereby activating Nrf2. Moreover, the BDL-induced liver fibrosis was markedly weakened in liver-specific Keap1 knockout mice. Hence, this study suggests that FTA alleviated the BDL-induced liver fibrosis through attenuating mitochondrial damage and ferroptosis in hepatocytes by activating Nrf2 via directly binding to Keap1.
PROBLEM TO BE SOLVED: To obtain a composition for oral cavity having high chemical cleaning effect. SOLUTION: This composition is obtained by blending >=3wt.% water-soluble pyrophosphoric acid salt, one or more kinds of straight-chain and cyclic water- soluble polyphosphoric acid salts represented by the formula Mn+2 Pn O3n+1 and the formula (MPO3 )m (M is Na or K; (m) and (n) are each >=3) in an amount of 20-100wt.% based on the water-soluble pyrophosphoric acid salt with a composition for oral cavity composed of components not releasing calcium ion and controlling pH of the blend to pH6-10. The composition is prepared into a dentifrice such as a toothpaste, a mouth rinsing agent, a troche, a chewing gum, etc., and used. The composition effectively removes stain of tooth surface, e.g. stain plaque or tobacco tar by chemical action and enables cleaning of a part which tooth brush does not reach and increases beautifying and whitening effect of tooth surface.  Further, since the composition has excellent cleaning effect, the composition can reduce blend amount of polisher when dentifrice is prepared.
BACKGROUND: Vaginal fistula (VF) affects 2-3 million women globally, with the majority in Africa. In Uganda, it's 2%, with western Uganda having the highest prevalence. Major predisposing factors for refugee women include health system breakdowns and sexual violence during conflict. VF has severe consequences for women, relatives, and communities. There's limited information on lived experiences among refugee women with VF, and there's a need for quality prevention, treatment, and social reintegration strategies. This study aimed to understand the physical, psychosocial, and economic impacts of VF on refugee women in Nakivale and Oruchinga settlements and their coping mechanisms.
METHODS: Ten refugee women with VF were interviewed using qualitative study design, utilizing Social-Ecological and Transactional Models for data collection, analysis, and discussion.
RESULTS: Ten refugee women aged 24-50 years with or who had experienced VF participated in the study. They lived with VF for at least 2-15 years and had multiple stillbirths. Obstetric Fistula (OF) was the leading cause, followed by rape and cancer. Post-fistula, they faced social discrimination, emotional disturbances, survival difficulties, poverty, and lack of support. They struggled with stigma, social isolation, and marital sexual challenges.
CONCLUSION: Refugee women experience physical, emotional, financial, social, and sexual trauma due to VF. Discrimination and stigmatization from loved ones and society lead to isolation, depression, and suicidal thoughts. Despite successful repair, their social and emotional healing remains a burden for their lives. There is a need to provide a supportive environment for VF survivors.
A computer implemented method for selecting targeted digital impressions based upon unifying digital identity data for computers, devices, accounts or users to data source from third parties that can support defining targeted audiences for campaigns and delivering highly relevant impressions to members of the target audiences. A DSP campaign planning system receives one or more NPIs of one or more HCPs, practice data indexed by the NPIs, and one or more of prescription data specifying drug prescriptions previously written and indexed by the NPIs and/or clinical medical data indexed by the NPIs. The practice data, prescription data, clinical medical data, medical claims data, demographic data, practice/specialty data, address data, education data or other datasets may be mapped to or associated with NPI values in a database of digital identity data such as cookies or device IDs shared by the DSP campaign planning system and a DSP. The DSP campaign planning system supports defining target audiences, based upon the NPIs, practice data associated with the NPIs, and one or more of the prescription data, the clinical medical data, and the medical claims data, representing a campaign plan for targeting digital impressions to a specified HCP audience segment. Such campaigns may be executed based upon matching NPIs of user devices to cookie data represented in the plans. Audience data is transmitted to a DSP programmed to transmit digital instructions to an advertising exchange server for executing one or more targeted digital impressions via a media and advertisement display channel and user computer. Reporting and measurement functions may be programmed as part of the DSP campaign planning system.